

(12)

EUROPEAN PATENT SPECIFICATION

(45)

Date of publication and mention of the grant of the patent:  
05.03.2003 Bulletin 2003/10

(21)

Application number: 93112181.8

(22)

Date of filing: 29.07.1993

(51)

Int Cl.7: A61K 31/05, A61K 31/165, A61K 31/215, A61K 31/235, A61K 31/415, A61K 31/505, A61K 31/535, A61P 9/10, A61P 3/06

(54) **Pharmaceutical composition and method for treating hyperlipidemia and arteriosclerosis**  
Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arteriosklerose  
Composition pharmaceutique et méthode pour le traitement de l'hyperlipémie et de l'arteriosclérose

<div>(84) Designated Contracting States: CH DE FR GB IT LI</div> <div>(30) Priority: 30.07.1992 JP 20412292 02.09.1992 JP 23476792</div> <div>(43) Date of publication of application: 23.02.1994 Bulletin 1994/08</div> <div>(73) Proprietor: FUJI PHOTO FILM CO., LTD. Kanagawa-ken (JP)</div> <div>(72) Inventors:<ul style="list-style-type: none"><li>Aikawa, Kazuhiro, c/o Fuji Photo Film Co., Ltd. Minami-Ashigara-shi, Kanagawa-ken (JP)</li><li>Aoki, Kozo, c/o Fuji Photo Film Co., Ltd. Minami-Ashigara-shi, Kanagawa-ken (JP)</li></ul></div> <div>(74) Representative: Hansen, Bernd, Dr. Dipl.-Chem. et al Hoffmann Eitle, Patent- und Rechtsanwälte, Arabellastrasse 4 81925 München (DE)</div>	<div>(56) References cited: EP-A- 0 074 341 EP-A- 0 167 943 EP-A- 0 352 864 US-A- 3 658 822</div> <div><ul style="list-style-type: none"><li>AMERICAN JOURNAL OF PATHOLOGY vol. 139, no. 1, 1 July 1991, pages 217 - 229 MCGUIRE E.J., ET AL., 'Peroxisome induction potential and lipid-regulating activity in rats'</li><li>S. BUDAVARI, ED. 'The Merck Index' 1989 , MERCK &amp; CO. , RAHWAY USA</li><li>S. BUDAVARI, ED. 'The Merck Index' 1989 , MERCK &amp; CO. , RAHWAY USA</li><li>INT. J. OBES. vol. 11, 1987, pages 619 - 629 F.M. WHITTINGTON ET AL. 'Effect of sodium 2-n-pentadecyl-benzimidazole-5-carboxylate (M &amp; B 35347B) an inhibitor of acetyl-CoA-carboxylase, on lipogenesis and fat deposition in obese hyperglycaemic (ob/ob) and lean mice'</li></ul></div> <div>Remarks: The file contains technical information submitted after the application was filed and not included in this specification</div>
---	--

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description


## Background of the Invention

**[0001]** The present invention relates to a novel pharmaceutical composition and method for treating hyperlipidemia and arteriosclerosis, more specifically to an antihyperlipidemia agent having a blood cholesterol lowering effect or an antiarteriosclerosis agent having a macrophage-foaming reaction suppressing effect and a method for treating hyperlipidemia and arteriosclerosis using this composition.

**[0002]** As people have become more affluent, their eating habits have changed toward increased intake of foods with high cholesterol content and high caloric value. As a result, hyperlipidemia and arteriosclerosis are increasing rapidly in conjunction with the aging of the population. This has become a major social problem.

**[0003]** Hitherto, drug therapy for hyperlipidemia and arteriosclerosis has been directed only to lowering blood cholesterol. No drug capable of reversing the effects of arteriosclerosis is available.

**[0004]** Arteriosclerosis is characterized by thickening of the blood vessel intima and lipid deposition within the blood vessel. Therefore, for drug therapy of the disease, drugs capable of lowering blood cholesterol have been used. However, it has been found that the macrophage-foaming reaction plays an important role in forming the focus of arteriosclerosis. Thus, it is expected that suppression of this reaction would result in regression of the arteriosclerosis foci. AM. J. Path. 1991, 139, pp. 217-229 discloses that various lipid-regulating agents induce hepatomegaly, hepatic peroxisome proliferation, and hepatocarcinoma in rats. One such compound is



## Summary of the Invention


**[0005]** A primary object of the present invention is to provide a novel and low toxic pharmaceutical composition capable of lowering blood cholesterol and suppressing macrophage-foaming reaction by way of inhibiting acyl-CoA cholesterolacyltransferase (ACAT) activity and intracellular cholesterol transport.


**[0006]** Another object of the present invention is to provide the use of certain compounds for the manufacture of medicaments for treating hyperlipidemia and arteriosclerosis.

**[0007]** These and other objects of the present invention will be apparent from the following description and Examples.

**[0008]** The above objects were achieved based on the discovery that certain benzimidazole and 2,2'-methylenebisphenol derivatives have not only an ACAT activity-inhibiting effect, an intracellular cholesterol transport-inhibiting effect and an excellent blood cholesterol lowering effect but also a macrophage-foaming reaction suppressing effect, and, as such, are able to achieve the aforesaid object.

**[0009]** According to a first aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (II) or (III), or a pharmaceutically-acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent:





(III)

wherein

$R_1$  represents a hydrogen atom, an alkyl, an aryl, a mercapto, an alkylthio, and alkenylthio, an arylthio or a heterocyclo group;


$R_2$  represents a hydrogen atom or an alkyl group, provided that the alkyl group is not substituted by a hydroxyl group;

$R_3$  represents a hydrogen atom, a halogen atom, a nitro group,  $R_5O-$ ,  $R_5CONH-$ ,  $R_5NHCO-$ ,  $(R_5)_2NCO-$ ,  $R_5SO_2NH-$ ,  $R_5NHSO_2-$ ,  $R_5OCO-$ ,  $R_5COO-$  or  $R_5NHCONH-$  where  $R_5$  represents an alkyl or an aryl group; and

$R_6$  represents a divalent group.

**[0010]** According to a second aspect, the present invention provides the use of the compounds of the formula (II) or (III), or a pharmaceutically-acceptable salt thereof, as defined above, for the manufacture of a pharmaceutical composition for treating hyperlipidemia and arteriosclerosis in a mammal, preferably man.

**[0011]** According to a third aspect, the present invention provides the use of a compound of formula (I):



(I)

wherein

$R_1$  represents a hydrogen atom, an alkyl, a mercapto, an alkylthio, an alkenylthio, an arylthio or a heterocyclo group;

$R_2$  represents a hydrogen atom or an alkyl group optionally substituted by an aryl, an amino or an acylamino group; and

$R_3$  and  $R_4$  each independently represents a hydrogen atom, a halogen atom, a nitro group,  $R_5O-$ ,  $R_5CONH-$ ,  $R_5NHCO-$ ,  $(R_5)_2NCO-$ ,  $R_5SO_2NH-$ ,  $R_5NHSO_2-$ ,  $R_5OCO-$ ,  $R_5COO-$  or  $R_5NHCONH-$  where  $R_5$  represents an alkyl or an aryl group, for the manufacture of a pharmaceutical composition for treating hyperlipidemia and arteriosclerosis in mammals, preferably man.

Detailed explanation of preferred Embodiments

**[0012]** The present invention provides a pharmaceutical composition which has an excellent blood cholesterol lowering effect and macrophage-foaming reaction suppressing effect and is low in toxicity, it therefore exhibits an excellent therapeutic effect on hyperlipidemia and arteriosclerosis and is administrable over a long period.

**[0013]** Among the compounds of the formulae (I), (II) and (III), the compounds of the formula (I) are preferable and, in the compounds of the formula (I), the compounds of the following formula (V) are particularly preferable;



wherein

R<sub>3</sub> represents a hydrogen atom, a halogen atom, a nitro group, R<sub>5</sub>O-, R<sub>5</sub>CONH-, R<sub>5</sub>NHCO-, R<sub>5</sub>NHSO<sub>2</sub>- or R<sub>5</sub>SO<sub>2</sub>NH- where R<sub>5</sub> represents an alkyl group.

15

20

25

30

40

35





45




50




55




**[0025]**  $-(\text{CH}_2)_n-$  and  $-\text{NHCO}(\text{CH}_2)_n\text{CONH}-$  where n is 2 to 8 are particularly preferable.

**[0027]** Examples of the pharmaceutically-acceptable salts of the compounds represented by the formulae (I), (II) and (III) include hydrochloride, hydrobromide, nitrate, sulfate and toluenesulfonate. Hydrochloride is particularly preferable.







































































(48)



(49)



(50)



[0029] The method for preparing these compounds will now be described in detail.

[0030] Benzimidazole ring which is basic skeleton of the compounds of the formulae (I), (II) and (III) is generally synthesized using a o-phenylenediamine as a starting material. That is 2-mercaptobenzimidazoles are generally synthesized by reacting o-phenylenediamines with carbon disulfide under a basic condition and 2-alkyl- or 2-aryl benzimidazoles are generally synthesized by reacting o-phenylenediamines with carboxylate or orthocarboxylate under an acidic condition.

#### Synthesis Example 1 Synthesis of 2-methyl-5-nitrobenzimidazole (5)

[0031] 15.3 g of 3,4-dinitrobenzene was added to 64 ml of acetic anhydride and 2 ml of conc. hydrochloric acid and the mixture was refluxed for 3 hours. After cooling, the formed crystals were dispersed in 10 % sodium hydroxide aqueous solution and then filtered off. The crystals were recrystallized from water-containing ethanol to obtain 6 g of compound (5).

Melting point	220-221 °C		
Elemental analysis (%)	Anal.	C 54.42	H 4.03 N 23.62
	Cal.	C 54.23	H 3.98 N 23.72

#### Synthesis Example 2 Synthesis of 1,8-bis(5-nitrobenzimidazol-2-yl) octane (6)

[0032] 10.8 g of o-phenylenediamine and 10.1 g of sebacic acid were added to 120 ml of 4 N hydrochloric acid and the mixture was refluxed for 6 hours. After cooling, the formed crystals were filtered off and washed with 1 N sodium carbonate aqueous solution until the washing solution maintained an alkalinity. After separating and drying the crystals, they were dissolved in 35 ml of conc. sulfuric acid and 3.8 g of potassium nitrate was added thereto little by little while stirring under cooling with ice. After stirring for 2 hours under cooling with ice, the solution was poured into ice-water and the formed crystals were washed with 1 N sodium carbonate aqueous solution until the washing solution maintained an alkalinity. The crystals were recrystallized from water-containing ethanol to obtain 3.4 g of compound (6).

Melting point	135-137 °C		
Elemental analysis (%)	Anal.	C 60.62	H 19.25 N 5.41
	Cal.	C 60.54	H 19.26 N 5.54

#### Synthesis Example 3 Synthesis of 2-mercapto-5-methoxybenzimidazole(13)

[0033] 70 ml of ethanol and 15 ml of carbon disulfide were added to 2.6 g of 3,4-diaminoanisole and then a solution of 1.5 g of sodium hydroxide in 5 ml of water was added thereto. After heating with a water bath for 3.5 hours, the mixture was cooled with ice, filtered and then the solvent in the filtrate was distilled off under reduced pressure. The residue was dissolved in ethanol. The solution was filtrated to remove the insoluble matter and then the solvent in the filtrate was distilled off under reduced pressure. The residue was recrystallized from water-containing methanol to obtain 2.0 g of the titled compound (13).

## EP 0 583 665 B1

Melting point	254-255 °C
Elemental analysis (%)	Anal. C 53.06 H 4.52 N 15.27
	Cal. C 53.33 H 4.44 N 15.56

### Synthesis Example 4 Synthesis of 2-benzylthiobenzimidazole (7)

**[0034]** 15 g of 2-mercaptobenzimidazole and 16.5 g of benzylbromide were dissolved in 50 ml of ethanol and the mixture was refluxed with a water bath for 5 hours. After cooling, the formed crystals were collected and recrystallized from ethanol to obtain 18 g of compound (7).

Melting point	185-186 °C
Elemental analysis (%)	Anal. C 69.59 H 5.30 N 11.74
	Cal. C 69.99 H 5.03 N 11.66

### Synthesis Example 5 Synthesis of 5-dodecanoylamino-2-mercaptobenzimidazole (8)

**[0035]** 5 g of 5-amino-2-mercaptobenzimidazole was dissolved in 50 ml of pyridine and 7.95 g of dodecanoyl chloride was added dropwise thereto under cooling with ice. After stirring for 3 hours at room temperature, the solution was poured into ice-water. The formed crystals were filtered off and recrystallized from water-containing methanol to obtain 10.9 g of compound (8).

Melting point	266-267 °C
Elemental analysis (%)	Anal. C 66.38 H 8.54 N 11.34
	Cal. C 65.71 H 8.36 N 12.10

### Synthesis Example 6 Synthesis of 2-morpholinomethylbenzimidazole (36)

**[0036]** To 108 g of o-phenylenediamine, 1 ℓ of 4 N hydrochloric acid and 142 g of chloroacetic acid were added and refluxed for 1.5 hours. After allowing to stand overnight, the solution was diluted with 2 ℓ of water and neutralized with dilute ammonia water. The formed crystals were filtered off to obtain 113 g of 2-chloromethylbenzimidazole.

**[0037]** 10 g of 2-chloromethylbenzimidazole thus obtained and 10.5 g of morpholine were dissolved in 75 ml of alcohol and the solution was refluxed for 3 hours. After cooling, ether was added to the solution and the precipitated crystals were filtered off. The filtrate was washed with water and saturated with hydrogen chloride to form an oily matter. The oily matter was crystallized by adding a small amount of alcohol and the crystals were filtered off. The crystals were recrystallized from alcohol to obtain 2.5 g of compound (36).

Melting point	235-236 °C
Elemental analysis (%)	Anal. C 49.48 H 5.88 N 14.27
	Cal. C 49.66 H 5.91 N 14.48

**[0038]** The following compounds were synthesized according to the method above described. The melting points of the crystalline compounds are as follows:

Compound No.	m.p.(°C)	Compound No.	m.p.(°C)
(1)	195-200 (HCl salt)	(2)	200-203
(3)	133-135 (HBr salt)	(4)	167-170
(5)	220-221	(6)	135-137
(7)	190-191	(8)	226-267
(9)	266-268	(10)	275-276
(11)	>300	(12)	>280
(13)	254-255	(14)	128-129
(15)	95-97	(16)	106-108

(continued)

Compound No.	m.p.(°C)	Compound No.	m.p.(°C)
(17)	181-183	(18)	119-123
(20)	84-87	(21)	183-186
(23)	250-252	(24)	214-217
(25)	200 (decomp.)	(26)	284-286
(27)	230-232	(28)	132-134
(29)	217 (decomp.)	(30)	243-245
(31)	143-144	(32)	>250
(33)	124-125	(34)	218-220
(35)	215-217 (HCl salt)	(36)	235 (decomp.) (HCl salt)
(37)	162-164	(38)	215-216
(39)	202-203	(42)	230-231
(43)	155-156	(44)	163-164
(45)	146 (decomp.)	(46)	197-199
(47)	54-56	(48)	60-63
(49)	82-85	(50)	188-191
(51)	209-212		

**[0039]** The pharmaceutical composition of the present invention may contain one or more compounds of formulae (II) to (III) and may be used in combination with the known antihyperlipidemia and antiarteriosclerosis agents that are conventionally used and are compatible with the compounds of the present invention. Examples of known antihyperlipidemia and antiarteriosclerosis agents include Melinamide, Probucol and Mevalotin.

**[0040]** The pharmaceutical composition of the present invention may be administered, for example, orally or by injection (mainly intramuscular, intravenous or subcutaneous route) and is usually prepared in the form of a formulation suitable for the administration route. Thus, the pharmaceutical composition can be used as an oral formulation such as tablet, powder, granule, capsule, syrup, emulsion, suspension or solution, or injection. The formulations can be prepared by mixing the compound of the present invention with a pharmaceutical-acceptable carrier, diluent and/or bioactive substance.

**[0041]** Examples of pharmaceutical carriers or diluents suitable for combining with the compound of formula (I) to (III) include glucose; saccharose; lactose; ethanol; glycerin; mannitol; sorbitol; pentaerythritol; diethylene glycol, triethylene glycol, ethylene glycol, propylene glycol, dipropylene glycol, polyethylene glycol 400, other polyethylene glycols than polyethylene glycol 400; mono-, di- and triglycerides of saturated fatty acids such as triauryl glyceride, monostearoyl glyceride, tristearoyl glyceride and distearoyl glyceride; pectin; starch; corn starch; arginic acid; xylose; talc, lycopodium; oils and fats such as olive oil, peanut oil, castor oil, corn oil, wheat malt oil, sesame oil, cottonseed oil, sunflower oil and cod-liver oil; gelatin; lecithin; silica; cellulose; cellulose derivatives such as hydroxypropyl methyl cellulose, methylcellulose, hydroxyethyl cellulose and calcium carboxymethyl cellulose; magnesium or calcium salts of fatty acids having 12 to 22 carbon atoms such as calcium stearate, calcium laurate, magnesium oleate, calcium palmitate, calcium behenate and magnesium stearate; cyclodextrins such as  $\alpha$ -cyclodextrin,  $\beta$ -cyclodextrin,  $\gamma$ -cyclodextrin, hydroxyethyl- $\beta$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dihydroxypropyl- $\beta$ -cyclodextrin, carboxymethyl ethyl- $\beta$ -cyclodextrin and dimethyl- $\beta$ -cyclodextrin; emulsifiers such as esters of saturated and unsaturated fatty acids having 2 to 22, particularly 10 to 18 carbon atoms, with monovalent aliphatic alcohols (for example, alkanols having 1 to 20 carbon atoms such as glycol, glycerin, diethylene glycol, pentaerythritol, ethanol, butanol and octadecanol) or polyvalent alcohols; silicones such as dimethyl polysiloxane; and pyrogen-free distilled water.

**[0042]** The dosage of the pharmaceutical composition of the present invention varies depending on age, body weight, severity of the disease of the patient and the administration route. However, in general, the quantity of the compound of formula (I), (II) and/or (III) to be administered ranges from 0.1 to 500 mg, preferably from 0.2 to 100 mg per day per kg of body weight for adult.

#### Pharmaceutical test

(1) In vitro test for suppressing effect of macrophage-foaming reaction using mouse abdominal cavity macrophage

**[0043]** A 15-week old ICR female mouse (Japan SLC) was amputated at its neck and exsanguinated. Then, Hanks

buffer (Nissui Pharmaceutical Co., Ltd.) was injected intraperitoneally. After massaging the abdominal part, the buffer was recovered rapidly and centrifuged at 1,000 rpm for 5 minutes to collect the abdominal cavity macrophage. Then, the collected abdominal cavity macrophage was suspended in GIT medium (Wako Pure Chemical Industry) and inoculated on a 24-well microplate. After culturing the macrophage for 2 hours at 37 °C in 5 % CO<sub>2</sub>, the medium was changed into Dulbecco modified Eagle's MEM medium (Nissui Pharmaceutical Co., Ltd.). After further culturing the macrophage for 16 hours at 37 °C in 5 % CO<sub>2</sub>, the following substances were added in order:

① Test compounds: solutions in DMSO (Wako Pure Chemical Industry) 1 ml of the solutions were prepared, optionally diluted and the diluted solutions were added to individual wells (500 µl) in the amount of 5 µl.

② Liposome

PC/PS/DCP/CHOL. 50/50/10/75 (nmol)

PC : phosphatidylcholine (Funakoshi)

PS : phosphatidylserine (Funakoshi)

DCP : dicetylphosphate (Funakoshi)

CHOL. : cholesterol (Sigma)

③ <sup>3</sup>H-Oleic acid (Amersham Japan)

**[0044]** Then, after still further culturing the macrophage for 16 hours at 37 °C in 5 % CO<sub>2</sub>, the lipid fraction was extracted with chloroform and methanol. The extracted lipid fraction was subjected to TLC (hexane:ether:acetic acid = 70:30:1), the separated bands of CE (cholesteryl ester) and TG (triglyceride) were borne off from the TLC plate and then the radioactivities thereof were measured using a liquid scintillation counter (PACKARD BH-22). Yields of cholesteryl ester were calculated by comparing with a control. The results are shown in Table 1.

Table 1

Compound No.	Dosage	Yield of CE (%)	Yield of TG (%)
(3)	5 µM	69	89
(5)	5 µM	67	89
(6)	5 µM	8.0	61
(7)	5 µM	61	91
(8)	5 µM	42	106
(10)	5 µM	69	129
(12)	5 µM	52	102
(20)	5 µM	49	62
(21)	5 µM	64	93
(23)	5 µM	56	119
(27)	5 µM	51	78
(28)	5 µM	53	164
(30)	5 µM	51	91
(34)	5 µM	50	108
(42)	5 µM	61	96
(43)	5 µM	45	98
(47)	5 µM	55	98

**[0045]** It is clear from Table 1 that these compounds do not lower the yield of TG so far, that is, these compounds are low toxic and capable of markedly suppressing the yield of CE. Namely, these compounds markedly suppress the macrophage-foaming reaction without being highly toxic to the macrophage.

(2) Blood lipid lowering effect in rabbit fed high-cholesterol feed

**[0046]** (i) New Zealand White female rabbits having body weight of about 2 kg were fed feed having high cholesterol content (100g/day/rabbit: ORC-4 manufactured by Oriental Yeast, containing 0.5 % of cholesterol and 0.5 % of olive oil) for 7 days to produce hypercholesterolemia.

**[0047]** Subsequently, one group consisting of 3 rabbits (treatment group) was fed the same feed in the same amount, except that the feed further contained test compound (8) in the amount of 10 0mg/kg/day/rabbit, for 7 successive days. On the other hand, as a control, another group consisting of 3 rabbits was fed the same feed in the same amount

without any test compound.

**[0048]** A small amount of blood was drawn from the parotic vein of every rabbit once a week and was measured for amount of blood total cholesterol using IATROLIPO TC manufactured by latron Laboratories Inc.

**[0049]** The amount of blood total cholesterol of the treatment group fell by 25 % in comparison with the control group (3 rabbits).

**[0050]** Thus, it is clear that test compound (8) has an excellent lowering effect of the blood cholesterol.

(3) Blood lipid lowering effect in rabbit fed normal feed

**[0051]** (i) New Zealand White female rabbits having body weight of about 2 kg were fed normal feed (100g/day/rabbit: ORC-4 manufactured by Oriental Yeast) for 7 days.

**[0052]** Subsequently, one group consisting of 3 rabbits (treatment group) was fed the normal feed in the same amount, except that the feed further contained test compound (2) in the amount of 10 0mg/kg/day/rabbit, for 7 successive days. As a control, another group consisting of 3 rabbits was fed the normal feed in the same amount without any test compound.

**[0053]** A small amount of blood was drawn from the parotic vein of every rabbit once a week and was measured for amount of blood total cholesterol using IATROLIPO TC manufactured by latron Laboratories Inc.

**[0054]** The amount of blood total cholesterol of the treatment group fell by 20 % in comparison with the control group' (3 rabbits).

**[0055]** Thus, it is clear that test compound (2) has an excellent blood cholesterol lowering effect not only on rabbits fed high-cholesterol feed but also on rabbits fed normal feed.

(4) Acute toxicity test

**[0056]** Compound (2) was suspended in 0.5 % Tween 80 solution. Six 8-week old ddy mice were orally administered the suspension and were observed on acute toxicity. As a result, the LD50 value of the compounds of the present invention were found to be not less than 1000 mg/kg. This value indicates that the compounds of the present invention is low in toxicity.

Examples

Example 1 Tablet

**[0057]** Preparation of tablet containing 25 mg of compound (8)

①	compound (8)	10 g
②	corn starch	40 g
③	crystalline cellulose	45 g
④	calcium carboxymethyl cellulose	4 g
⑤	light silicic acid anhydride	500 mg
⑥	magnesium stearate	500 mg
Total		100 g

**[0058]** ① to ⑤ were homogeneously mixed and the resulting mixture was compression molded with a tableting machine to obtain tablets having weight of 250 mg. Each of these tablets contained 25 mg of compound (8). An adult may take 5 to 30 tablets over the course of one day.

Example 2 Capsule

**[0059]** Preparation of capsule containing 40 mg of compound (8)

①	compound (8)	20 g
②	corn starch	79.5 g
③	light silicic acid anhydride	500 mg
Total		100 g

[0060] ① to ③ were homogeneously mixed and the resulting mixture was encapsulated in the amount of 200 mg per capsule. Each of thus-obtained capsules contained 40 mg of compound (8). An adult may take 1 to 20 capsules over the course of one day.

### Example 3 Granule



[0061] Preparation of granule containing 100 mg of compound (8) per 1 g

①	compound (8)	10 g
②	corn starch	40 g
③	10% hydroxypropyl cellulose solution in ethanol	50 g
Total		100 g

[0062] ① to ③ were homogeneously mixed. After kneading, the mixture was granulated with a granulating machine and dried to obtain granules. These capsules contained 100 mg of compound (8) per 1 g. An adult may take 1 to 8 g over the course of one day.

### Claims

1. A pharmaceutical composition comprising a compound of formula (II) or (III), or a pharmaceutically-acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent:



wherein

$R_1$  represents a hydrogen atom, an alkyl, an aryl, a mercapto, an alkylthio, and alkenylthio, an arylthio or a heterocyclo group;

$R_2$  represents a hydrogen atom or an alkyl group, provided that the alkyl group is not substituted by a hydroxyl group;

$R_3$  represents a hydrogen atom, a halogen atom, a nitro group,  $R_5O-$ ,  $R_5CONH-$ ,  $R_5NHCO-$ ,  $(R_5)_2NCO-$ ,  $R_5SO_2NH-$ ,  $R_5NHSO_2-$ ,  $R_5OCO-$ ,  $R_5COO-$  or  $R_5NHCONH-$  where  $R_5$  represents an alkyl or an aryl group; and


$R_6$  represents a divalent group.

2. The use of a compound of the formula (II) or (III), or a pharmaceutically-acceptable salt thereof, as defined in Claim 1, for the manufacture of a pharmaceutical composition for treating hyperlipidemia and arteriosclerosis in mammals,



preferably man.

3. The use of a compound of formula (I):



wherein


$R_1$  represents a hydrogen atom, an alkyl, a mercapto, an alkylthio, an alkenylthio, an arylthio or a heterocyclo group;

$R_2$  represents a hydrogen atom or an alkyl group optionally substituted by an aryl, an amino or an acylamino group; and provided that the alkyl group is not substituted by a hydroxyl group;

and  $R_3$  and  $R_4$  each independently represents a hydrogen atom, a halogen atom, a nitro group,  $R_5O-$ ,  $R_5CONH-$ ,  $R_5NHCO-$ ,  $(R_5)_2NCO-$ ,  $R_5SO_2NH-$ ,  $R_5NHSO_2-$ ,  $R_5OCO-$ ,  $R_5COO-$  or  $R_5NHCONH-$  where  $R_5$  represents an alkyl or an aryl group,

for the manufacture of a pharmaceutical composition for treating hyperlipidemia and arteriosclerosis in mammals, preferably man.

4. The use according to Claim 3, wherein the compound of the formula (I) is represented by the following formula (V);



wherein

$R_1$  represents a hydrogen atom, an alkyl, a mercapto or an alkylthio group; and

$R_3$  represents a hydrogen atom, a halogen atom, a nitro group,  $R_5O-$ ,  $R_5CONH-$ ,  $R_5NHCO-$ ,  $R_5NHSO_2-$  or  $R_5SO_2NH-$  where  $R_5$  represents an alkyl group.

5. The use according to Claim 4, wherein  $R_1$  represents a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, a mercapto group or an alkylthio group having 1 to 18 carbon atoms; and  $R_5$  represents an alkyl group having 1 to 20 carbon atoms.



6. The use according to Claim 5, wherein

$R_1$  represents a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a mercapto group or an alkylthio group having 1 to 8 carbon atoms; and

$R_5$  represents an alkyl group having 4 to 18 carbon atoms.

## Patentansprüche

1. Pharmazeutische Zusammensetzung enthaltend eine Verbindung der Formel (II) oder (III) oder ein pharmazeutisch annehmbares Salz davon zusammen mit einem pharmazeutisch annehmbaren Träger oder Verdünner:



worin

R<sub>1</sub> ein Wasserstoffatom, eine Alkyl-, eine Aryl-, eine Mercapto-, eine Alkylthio-, eine Alkenylthio-, eine Arylthio- oder eine Heterocyclo-Gruppe darstellt;


R<sub>2</sub> stellt dar ein Wasserstoffatom oder eine Alkyl-Gruppe, vorausgesetzt, daß die Alkyl-Gruppe nicht mit einer Hydroxyl-Gruppe substituiert ist;

R<sub>3</sub> stellt dar ein Wasserstoffatom, ein Halogenatom, eine Nitro-Gruppe, R<sub>5</sub>O-, R<sub>5</sub>CONH-, R<sub>5</sub>NHCO-, (R<sub>5</sub>)<sub>2</sub>NCO-, R<sub>5</sub>SO<sub>2</sub>NH-, R<sub>5</sub>NHSO<sub>2</sub>-, R<sub>5</sub>OCO-, R<sub>5</sub>COO- oder R<sub>5</sub>NHCONH-, worin R<sub>5</sub> eine Alkyl- oder eine Aryl-Gruppe darstellt und

R<sub>6</sub> stellt eine zweiwertige Gruppe dar.

2. Die Verwendung einer Verbindung der Formel (II) oder (III) oder eines pharmazeutisch annehmbaren Salzes davon, gemäß Anspruch 1, zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hyperlipidämie oder Arteriosklerose in Säugetieren bevorzugt Mensch.

3. Verwendung einer Verbindung gemäß Formel (I):



worin


R<sub>1</sub> ein Wasserstoffatom, eine Alkyl-, eine Mercapto-, eine Alkylthio-, eine Alkenylthio-, eine Arylthio- oder Heterocyclo-Gruppe darstellt;

R<sub>2</sub> stellt dar ein Wasserstoffatom oder eine Alkyl-Gruppe, gegebenenfalls substituiert mit einer Aryl-, eine Amino- oder einer Acylamino-Gruppe und vorausgesetzt, daß die Alkyl-Gruppe nicht mit einer Hydroxyl-Gruppe substituiert ist, und

R<sub>3</sub> und R<sub>4</sub> stellen unabhängig dar ein Wasserstoffatom, ein Halogenatom, eine Nitro-Gruppe, R<sub>5</sub>O-, R<sub>5</sub>CONH-, R<sub>5</sub>NHCO-, (R<sub>5</sub>)<sub>2</sub>NCO-, R<sub>5</sub>SO<sub>2</sub>NH-, R<sub>5</sub>NHSO<sub>2</sub>-, R<sub>5</sub>OCO-, R<sub>5</sub>COO- oder R<sub>5</sub>NHCONH-, wobei R<sub>5</sub> darstellt eine Alkyl- oder eine Aryl-Gruppe,

zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hyperlipidämie und Arteriosklerose in Säugetieren, bevorzugt Mensch.

4. Verwendung gemäß Anspruch 3, wobei die Verbindung der Formel (I) dargestellt wird durch die folgende Formel (V):





worin

$R_1$  darstellt ein Wasserstoffatom, eine Alkyl-, eine Mercapto- oder eine Alkylthio-Gruppe und  $R_3$  stellt dar ein Wasserstoffatom, ein Halogenatom, eine Nitro-Gruppe,  $R_5O^-$ ,  $R_5CONH^-$ ,  $R_5NHCO^-$ ,  $R_5NHSO_2^-$  oder  $R_5SO_2NH^-$  wobei  $R_5$  eine Alkyl-Gruppe darstellt.

5. Verwendung gemäß Anspruch 4, wobei  $R_1$  darstellt ein Wasserstoffatom, eine Alkyl-Gruppe mit 1 bis 18 Kohlenstoffatomen, eine Mercapto-Gruppe oder eine Alkylthio-Gruppe mit 1 bis 18 Kohlenstoffatomen und  $R_5$  stellt eine Alkyl-Gruppe mit 1 bis 20 Kohlenstoffatomen dar.
6. Verwendung gemäß Anspruch 5, wobei  $R_1$  darstellt ein Wasserstoffatom, eine Alkyl-Gruppe mit 1 bis 8 Kohlenstoffatomen, eine Mercapto-Gruppe oder eine Alkylthio-Gruppe mit 1 bis 8 Kohlenstoffatomen und  $R_5$  stellt eine Alkyl-Gruppe mit 4 bis 18 Kohlenstoffatomen dar.

## Revendications

1. Composition pharmaceutique comprenant un composé de formule (II) ou (III), ou un sel pharmaceutiquement acceptable de celui-ci, ainsi qu'un support ou diluant pharmaceutiquement acceptable :



où

$R_1$  représente un atome d'hydrogène, un groupe alkyle, aryle, mercapto, alkylthio, alcénylthio, arylthio ou hétérocyclo ;


$R_2$  représente un atome d'hydrogène ou un groupe alkyle, à condition que le groupe alkyle ne soit pas substitué par un groupe hydroxyle ;

$R_3$  représente un atome d'hydrogène, un atome d'halogène, un groupe nitro,  $R_5O-$ ,  $R_5CONH-$ ,  $R_5NHCO-$ ,  $(R_5)_2NCO-$ ,  $R_5SO_2NH-$ ,  $R_5NHSO_2-$ ,  $R_5OCO-$ ,  $R_5COO-$  ou  $R_5NHCONH-$  où  $R_5$  représente un groupe alkyle ou aryle ; et

$R_6$  représente un groupe divalent,

2. Utilisation d'un composé de formule (II) ou (III), ou d'un sel pharmaceutiquement acceptable de celui-ci, selon la revendication 1, pour la fabrication d'une composition pharmaceutique pour traiter l'hyperlipidémie et l'artériosclérose chez les mammifères, de préférence l'homme.

3. Utilisation d'un composé de formule (I) ;



où


$R_1$  représente un atome d'hydrogène, un groupe alkyle, mercapto, alkylthio, alcénylthio, arylthio ou hétérocyclo ;

$R_2$  représente un atome d'hydrogène ou un groupe alkyle éventuellement substitué par un groupe aryle, amino ou acylamino ; et à condition que le groupe alkyle ne soit pas substitué par un groupe hydroxyle ; et

$R_3$  et  $R_4$  représentent chacun indépendamment un atome d'hydrogène, un atome d'halogène, un groupe nitro,  $R_5O-$ ,  $R_5CONH-$ ,  $R_5NHCO-$ ,  $(R_5)_2NCO-$ ,  $R_5SO_2NH-$ ,  $R_5NHSO_2-$ ,  $R_5OCO-$ ,  $R_5COO-$  ou  $R_5NHCONH-$ , où  $R_5$  représente un groupe alkyle ou aryle,

pour la fabrication d'une composition pharmaceutique pour traiter l'hyperlipidémie et l'artériosclérose chez les mammifères, de préférence l'homme.

4. Utilisation selon la revendication 3, où le composé de formule (I) est représenté par la formule (V) suivante :



où

$R_1$  représente un atome d'hydrogène, un groupe alkyle, mercapto ou alkylthio ; et

$R_3$  représente un atome d'hydrogène, un atome d'halogène, un groupe nitro,  $R_5O-$ ,  $R_5CONH-$ ,  $R_5NHCO-$ ,  $R_5NHSO_2-$  ou  $R_5SO_2NH-$ , où  $R_5$  représente un groupe alkyle.

5. Utilisation selon la revendication 4, où

$R_1$  représente un atome d'hydrogène, un groupe alkyle ayant 1 à 18 atomes de carbone, un groupe mercapto ou un groupe alkylthio ayant 1 à 18 atomes de carbone ; et

$R_5$  représente un groupe alkyle ayant 1 à 20 atomes de carbone.

6. Utilisation selon la revendication 5, où

$R_1$  représente un atome d'hydrogène, un groupe alkyle ayant 1 à 8 atomes de carbone, un groupe mercapto ou un groupe alkylthio ayant 1 à 8 atomes de carbone ; et

$R_5$  représente un groupe alkyle ayant 4 à 18 atomes de carbone.